Connexin43 hemichannel block protects against the development of diabetic retinopathy signs in a mouse model of the disease
- 8 December 2018
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 97 (2) , 215-229
Abstract
Diabetic retinopathy (DR) is a vascular disease of the neuroretina characterised by hyperglycaemia and inflammation. Current DR therapies target late-stage vascular defects and there is evidence to suggest that they contribute to geographic atrophy and retinal ganglion cell death long term. Therefore, alternative treatments that target common upstream disease mechanisms are needed. Recent studies have shown that connexin43 hemichannel blockers can reduce inflammation and prevent vessel leak in brain and spinal cord lesions. The aim of this study was to evaluate the effectiveness of a connexin43 hemichannel blocker (Peptide5) in a mouse model of DR in which pro-inflammatory cytokines, IL-1β and TNF-α, were intravitreally injected into non-obese diabetic (NOD, hyperglycaemic) mice. Fundus and optical coherence tomography images were taken to evaluate vessel dilation and beading as well as retinal and vitreous hyper-reflective foci (HRF). Immunohistochemistry was performed to assess levels of astrogliosis, microgliosis and inflammasome activation. Results showed that Peptide5 injection lowered the incidence of vessel dilation and beading, decreased the severity of vitreous and retinal HRF, and reduced sub-retinal fluid accumulation compared to the vehicle group. Furthermore, Peptide5 led to reduced connexin43 and GFAP upregulation, inhibited microglial infiltration into the outer nuclear layer and prevented upregulation of inflammasome markers compared to vehicle. The present study provides evidence in support of Peptide5, and connexin43 hemichannel block in general, as a potential upstream approach for the treatment of DR.Keywords
Funding Information
- Auckland Medical Research Foundation (1117015)
- Lottery Health Research (NA)
This publication has 48 references indexed in Scilit:
- The inflammasome pathway is amplified and perpetuated in an autocrine manner through connexin43 hemichannel mediated ATP releaseBiochimica et Biophysica Acta (BBA) - General Subjects, 2018
- Characterizing the mode of action of extracellular Connexin43 channel blocking mimetic peptides in an in vitro ischemia injury modelBiochimica et Biophysica Acta (BBA) - General Subjects, 2017
- Role of Hemichannels in CNS Inflammation and the Inflammasome Pathway2016
- The NLRP3 Inflammasome and its Role in Age-Related Macular Degeneration2015
- Intravitreal injection of lipoamino acid-modified connexin43 mimetic peptide enhances neuroprotection after retinal ischemiaDrug Delivery and Translational Research, 2015
- Connexin and pannexin signaling pathways, an architectural blueprint for CNS physiology and pathology?Cellular and Molecular Life Sciences, 2015
- Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injuryBasic Research in Cardiology, 2012
- Regulation of Connexin43 Gap Junction Protein Triggers Vascular Recovery and Healing in Human Ocular Persistent Epithelial Defect WoundsThe Journal of Membrane Biology, 2012
- Connexin hemichannel blockade improves outcomes in a model of fetal ischemiaAnnals of Neurology, 2012
- Macular edema. A complication of diabetic retinopathySurvey of Ophthalmology, 1984